ANTX
ANTX
Positions held
Your positionsANTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships
2026-09-30 · GSK (LSE:GSK) The Latest Update Raises A Bigger Question
2026-09-28 · AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research
2026-09-28 · AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
2026-09-16 · AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
2026-08-24 · AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
2026-08-11 · AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Price (daily)
Full chart · RSI · MACD · patterns